Redcare Pharmacy stock gained 3.94 percent after outlook upgrade

Published on 10/07/2026 at 13:26 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Redcare Pharmacy stock was last at EUR 68.60 on Xetra on October 6, 2026. Preliminary German Rx revenue grew 56 percent in Q3 2026, while the full-year range reached EUR 730 million to EUR 760 million.

Automatisiertes Apotheken-Lager mit Robotersystem und unbeschrifteten Medikamentenboxen — Redcare Pharmacy (Shop Apoth), ISIN NL0012044747, zeigt automatisiertes Apotheken-Lager mit Roboter-Regalsystem und markenfreien Medikamentenschachteln, Illustration mit AI erstellt.

Redcare Pharmacy stock (ISIN NL0012044747) was last at EUR 68.60 on Xetra on October 6, 2026, up 3.94 percent from the previous session. The online pharmacy group had already raised its full-year 2026 outlook on September 28, with German prescription revenue emerging as the main growth driver.

Guidance rises on German prescriptions

According to Redcare Pharmacy on September 28, 2026, full-year total revenue growth guidance increased to 16% to 18% from 15% to 17%. The company raised its German Rx revenue range to EUR 730 million to EUR 760 million from EUR 680 million to EUR 720 million.

Preliminary figures cited in the same company release showed German Rx revenue growth of 51% year-on-year in September and 56% in the third quarter of 2026. The adjusted EBITDA margin guidance stayed at 2.5% to 3.0%, so the forecast upgrade is concentrated in sales growth rather than profitability.

Analysts see further upside

According to finanzen.ch on October 3, 2026, four analysts rated Redcare Pharmacy Buy and set an average price target of EUR 100.25. That target lies 46.1 percent above the EUR 68.60 Xetra price, while the published analyst table listed Deutsche Bank at EUR 104 and Jefferies at EUR 97.

The latest analyst view adds a valuation question to the operating story. Redcare must now convert the preliminary prescription momentum into reported quarterly revenue, while the unchanged margin range keeps execution and cost discipline central to the next update.

Q3 results arrive October 29

Redcare Pharmacy schedules its Q3 2026 interim statement and quarterly conference call for October 29, 2026. That release will test whether the 56% preliminary German Rx growth translated into the group figures investors are valuing against the EUR 100.25 consensus target.

Redcare Pharmacy stock was last at EUR 68.60 on Xetra on October 6, 2026. The session range was EUR 65.55 to EUR 68.70, leaving the stock EUR 19.15 below its 52-week high of EUR 87.75.